Marcia A. Kean Chief Executive Officer

Marcia Kean was appointed Chief Executive Officer of Feinstein Kean Healthcare (FKH) in December 2002. In that role, she leads a team of 60+ professionals located in Cambridge, Massachusetts; San Francisco, California; Iselin, New Jersey: and Washington, DC. Mrs. Kean has a 25+ year track record in the life sciences, counseling CEOs and senior leadership in the use of communications to meet science-driven business and organizational objectives.

In 2003, Mrs. Kean founded the first Molecular Medicine communications practice in the country, to help clients manage the opportunities and issues inherent in the molecular-based transformation of health care. She has subsequently become a thought leader in the field, through her publications (See How Molecular Medicine Transforms Policy and Everything Else) and speaking engagements in the United States and internationally. Mrs. Kean currently serves as an advisor to the Board of Directors of the Personalized Medicine Coalition, and was awarded that organization’s first Distinguished Service Award in 2006. She is also a member of the Genetics Advisory Council of the Harvard-Partners Center for Personalized Genetic Medicine. She served in 2006 as a member of a Personalized Medicine Expert Panel convened by the Office of the Assistant Secretary for Planning and Evaluation (ASPE) of the US Department of Health and Human Services, to explore factors related to the integration of personalized medicine into clinical and public health practice. She also served on the Planning Committee of the 2008 Personalized Health Care Summit chaired by Utah Governor Jon Huntsman and co-hosted by HHS Secretary Michael Leavitt and Clay Christensen of Harvard Business School. Since 2008, she has served as a member of the Evidence-Based Medicine Communications Collaborative of the Institute of Medicine.

FKH’s Molecular Medicine Practice provides strategy and communication counsel and services to government, academic, commercial and advocacy organizations focused on new technologies, products, policies and issues in the converging fields of molecular medicine and health care IT. FKH believes this arena differs from traditional biopharmaceutical and health care enterprises in that all its key target constituencies have new and different opportunities and concerns. It is therefore essential to address – early and simultaneously – all the strategic challenges of business strategy, organizational positioning, product positioning and marketing, branding, reimbursement, ethics and privacy, legislative affairs, patient and physician education, and corporate valuation and financing – to achieve success.

Mrs. Kean holds an MBA in Finance from New York University, and a BA from the University of California at Berkeley.